Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cxense ASA - Annual report 2018

Oslo, Norway - 10 April 2019 - Cxense ASA (OSE: CXENSE) today published its annual report for 2018. Cxense unlocks the power of data so that our clients can build personal, profitable customer relationships. Cxense’s world leading Data Management Platform (DMP) with Intelligent Personalization enables businesses to gather, analyze and act on data in real-time to increase conversion and revenue across all digital platforms. 2018 Highlights* Execution on strategy to focus on the growing Data Management with Intelligent Personalization core business and divestment of non-core assets

Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ) are hereby summoned to the annual general meeting on Thursday 9 May 2019 at 2 p.m. at the IVA’s conference center, Grev Turegatan 16, Stockholm. ParticipationShareholders who wish to participate in the meeting must (a) be recorded in the share register maintained by Euroclear Sweden AB on Friday 3 May 2019, and (b), notify the company of their intention to participate in the meeting not later than on Friday 3 May 2019 in writing to Medivir AB, c/o Euroclear Sweden, P.O. Box 191, SE-101 23 Stockholm, Sweden. Such notification can also be made by

Tokmanni Group Corporation will publish its first quarter 2019 business review on 25 April 2019

Tokmanni Group Corporation                      Investor news                                           10 April 2019 at 9:30 amTokmanni will publish its first quarter 2019 business review on 25 April at approximately 8:30 a.m. (Finnish time). The stock exchange release and the presentation materials in Finnish and in English will be available on the company's website at ir.tokmanni.fi as soon as possible after the publication of the report. Tokmanni’s CEO Mika Rautiainen and CFO Markku Pirskanen will present the review to analysts, investors and media representatives on the publication

Ovzon and Intelsat to Drive Global Innovation in Empowering High-Throughput Communications for Remote Users on Ultra-Small Terminals

Ovzon and Intelsat today entered into a multi-year $56 million agreement aimed at facilitating the development of Ovzon 3, which is expected to be launched in 2021. Ovzon has developed an end-to-end satellite broadband service. With the addition of the Ovzon 3, it will enable Intelsat, as the anchor customer, to deliver an unrivaled, global high-throughput service on ultra-small terminals.As provided by the agreement with Ovzon, Intelsat will offer a unique combination of high-speed connectivity with ultra-small terminals as a managed service to U.S. government and other customers. This

Ovzon Expands Reach Through Agreement with Intelsat

Faster speeds and higher throughput to ultra-small terminals provide ground-breaking solution for mission-critical communication needs of remote users Intelsat and Ovzon have entered into a multi-year agreement whereby Intelsat will provide service to Ovzon via two powerful steerable beams on Intelsat’s planned new satellite, Intelsat 39, expected to launch in the third quarter of 2019.  Intelsat 39 will provide services for network, video distribution and government customers in Africa, Europe, the Middle East and Asia.The Intelsat-enabled service will add to Ovzon’s existing capacity,

Vitrolife acquires artificial intelligence technology for embryo assessment

Vitrolife has acquired rights to a technology for assessing embryos based on time-lapse videos using artificial intelligence (“AI”) and entered into collaboration agreements to further develop the technology.Vitrolife has entered into transfer and collaboration agreements regarding a technology for assessing embryos with Virtus Health, a leading IVF clinic group based in Australia and Harrison.AI, a technology company specialising in the development of AI software in healthcare applications based in Australia. Using time-lapse videos during in vitro fertilisation (IVF), and before embryo

Probi publishes annual report for 2018

Probi's Annual Report for 2018 is now available on the company website, www.probi.com under Investor Relations. Distribution of the printed annual report will start during week 16 to shareholders who subscribe to our financial reporting. This information is information that Probi AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 8.30 CET on 10 April 2019. FOR FURTHER INFORMATION, CONTACT:Henrik Lundkvist, CFO, Probi, tel +46 46 286 89 41, e-post: henrik.lundkvist@probi.com ABOUT PROBIProbi AB is a Swedish

Proposal for new board members

Shareholders representing more than 20% of all shares and votes in Pharmacolog have announced that at the Annual General Meeting on April 29, 2019, they will propose a new board.The proposal proposes re-election of Erik Hedlund (chairman) and Olof Johansson and new election of Carl-Johan Spak and Ragnar Linder. All the proposed members have a long industrial background, many years of experience as entrepreneurs and relevant industry knowledge. The additions to the Board mean that the composition well represents the competencies that the company needs, to develop its commercial activities

ACTIVE REMODELING OF CERAMENT® INTO HUMAN BONE CONFIRMED IN UK STUDY

Lund, Sweden, 08.00 CET, 10 April 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announced the publication of new radiographic and histological data, which for the first time provides clinical evidence of CERAMENT® remodeling into bone in humans. “This publication describes for the first time in detail radiographic and histological features in humans, which demonstrate, that the radiographic changes seen over time are due to active bone formation and not residual bone graft substitute. This correlates with good clinical outcomes in a

ECCO wins Gold Medal at the New York Festivals TV & Film Award

Last night, ECCO took home a Gold Medal in the ‘employee engagement’ category at the New York Festivals TV & Film Award for portraying its employees in three employer branding films. “How and why we do things will always define who we are as a company. Letting our employees tell their personal stories is both authentic and inspiring and will help position ECCO as much more than a great place to work,” says ECCO’s CEO Steen Borgholm. New York Festivals TV & Film Awards honours film productions from over 50 countries, and mirrors today's global trends and the next generation of talented

Alimak Group publishes Annual Report for 2018

Alimak Group’s Annual Report 2018, including the sustainability report, has been published on www.alimakgroup.com in Swedish and English.The Annual Report will also be printed in a limited edition and can be ordered from investor@alimakgroup.com. Stockholm, 10 April 2019 Alimak Group AB For further information, please contact:Mathilda Eriksson, Investor Relations Manager, +46 8 402 14 41 This information is information that Alimak Group AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08.00 CET on 10 April

FarmPharma receives EU funding SME instrument Phase I

As previously announced, FarmPharma AB that is subsidiary to Double Bond Pharmaceutical Int. AB, has submitted an application to the European Commission for an SME instrument grant within the framework of the Horizon2020 program, where groundbreaking innovation projects with market-generating potential can be supported. The company funds alone to implement a more in-depth and up to date business plan for continued successful development of InterferOX. The project under the name InFarm has now been funded with the amount of SEK 500,000, which corresponds to the entire sought amount and is

Ambea publishes annual report for 2018 and presents additional information relating to the impact of IFRS 16

Ambea’s annual report for 2018 is published today in pdf-format on ambea.com and is also enclosed to this press release. A printed version will be available for distribution during week 18. In connection to the publication of Ambea’s annual report, Ambea presents updated information relating to the impact of IFRS16 on both Ambea and acquired Aleris Care. A summary is available on ambea.com.

Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer

10 April 2019 07:00 BST Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer AstraZeneca and MSD's Lynparza reduced the risk of disease progression or death by 42% vs. chemotherapy in Phase III OlympiAD trial First PARP inhibitor approved in the EU for patients with this difficult-to-treat disease and third EU approval for Lynparza AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib) as a monotherapy for

Q2: Sharp growth in LCP and SMB affected by temporary effects

Second quarter · Net sales rose 18.1 per cent to SEK 3,215 million (2,723). · Organic growth was 7.8 per cent (1.7), of which SMB accounted for 0.1 per cent (10.9), LCP for 16.1 per cent (neg: 5.0) and B2C for a negative 13.5 per cent (pos: 10.8). · The gross margin rose to 16.3 per cent (15.4). · Adjusted EBITA increased to SEK 154 million (143), corresponding to an adjusted EBITA margin of 4.8 per cent (5.3). · EBIT totalled SEK 160 million (131) including items affecting comparability of SEK 23.2 million (0.3). · Profit for the quarter amounted to SEK 124 million (92).

Water and shore construction skills gained in Finland would also benefit Sweden

YIT CORPORATION News, April 10, 2019 at 09:00 a.m.The key factors behind successful water and shore construction projects are careful planning, special expertise and seamless cooperation. The know-how gleaned from Finnish construction sites can also be exported to other countries, like Sweden, where there is a strong desire to better utilise the valuable shoreline areas. In the near future, the shoreline of important ports located by waterways is going through a change both in Finland and Sweden alike, as old port areas are developed and converted into residential and business areas.

Nanosatellites see the light - laser communication for a new age in space

TESAT, KSAT and GomSpace have partnered up to introduce full optical communications capability for new innovative small satellite missions and space-based services. Until now this technology has mainly been used on large and expensive satellites but is now further developed, miniaturised and ready for use on small satellites and new constellations. The new technology will be launched in the PIXL demonstration mission later in 2019. The benefits of optical communications in space Optical communication technology offers a number of important benefits that will add to the value of

Adjusted comparison figures due to changes in business segments

On 1 March, Handelsbanken carried out a reorganisation which has meant that certain operations in the Handelsbanken Sweden and Handelsbanken Capital Markets business segments have been moved over to Group IT and the newly formed unit Group Products and Services. Income and expenses relating to Group IT and Group Products and Services are reported within Other units. At the same time, the model for the internal capital allocation to the business segments has been adjusted somewhat. Recalculated comparison figures for the past eight quarters are available at http://www.handelsbanken.se/

Additional patent protection for melflufen granted in the US until 2033

Stockholm - 10 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. Oncopeptides has previously received the corresponding patent protection both in Japan and Europe.These patents (application numbers 14/438473 and 15/225323) protect, inter alia, the freeze-dried formulation. The patent protection extends to 2033. The freeze-dried preparation with melflufen is intended to be marketed at a future approval. “We have now approved formulation

MAG Interactive AB (publ) presents interim report Sep – Feb 2018/2019

Multiplayer games show continued revenue growth while user acquisition investments put pressure on the resultComment from CEO in summary “In line with our strategy multiplayer games are now growing steadily and represent about 70% of all revenues, up from less than 50% during the same period last year. Continued investments in performance marketing with good long-term returns, combined with improvements in our multiplayer games is the path back to profitability.”, says Daniel Hasselberg, CEO of MAG. “The negative result this quarter is an effect of user acquisition investments as the

Invitation to Kesko’s Q1/2019 interim report on 25 April 2019

A stock exchange release concerning Kesko Group’s Q1/2019 interim report will be published on Thursday, 25 April 2019, at about 9.00 (EET). Results conference, conducted in Finnish, will be held at 11.00 (EET) in Helsinki, Neptun building, Mannerheimintie 117. Coffee service available at 10.30. Webcast is available at www.kesko.fi/raporttikeskus. A transcript of the Q&A session will be available in English afterwards at www.kesko.fi/report-centre. An audiocast/teleconference, conducted in English, will be held at 14.00 (EET). A link to the audiocast/teleconference is available at www.

Corrected: Immunovia and University College of London sign agreement to expand validation studies of IMMray™ PanCan-d for early signs and symptoms

LUND, SWEDEN - Immunovia today announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London (UCL) will expand the prospective collection of blood samples funded by Immunovia and that started with the PanSYM-1 pilot study.The pilot PanSYM-1 study at UCL that started in 2017 (PR from November 2nd, 2017 ) is scheduled for readout in 2019 and, following today’s news, will now support the continuation of PanSYM-1 as a prospective validation study. The continued PanSYM-1 study

ChloraSolv receives CE marking and is cleared for commercial launch in EU

Gothenburg, Sweden, April 10th, 2019 – RLS Global AB announces that ChloraSolv, its wound care product targeting diabetic foot ulcers, has successfully obtained a CE marking based on confirmation from Lloyd’s Register, acting as Notified Body, and is therefore cleared in 32 European countries for commercialization.ChloraSolv is based on a Swedish innovation, which utilizes RLS Global’s proprietary buffered hypochlorite technology to debride and clean wounds to support the natural wound healing process. Clinical data has shown that ChloraSolv has unique properties with regards to cleansing

Fazer Group commits to cage-free eggs by 2024

Fazer is committed to using only cage-free eggs by 2024 in the Nordic and Baltic countries.Fazer’s commitment to cage-free eggs continues the company’s efforts in line with its sustainability approach and, especially, the core goal of 100% sustainably sourced. In Fazer’s revised sustainability approach, animal welfare was lifted as one of the essential topics, and the commitment to cage-free eggs supports the activities to be taken in this area. The commitment to cage-free eggs covers all Fazer’s businesses and countries of operation but, in the first phase, the focus will be on the Nordic

There are no items matching the current filter
There are no more items matching the current filter
Back to top